Abstract
Initial 1-year results from the pivotal KEYNOTE-024 (KN024) trial showed improved efficacy of pembrolizumab over chemotherapy in advanced non-small cell lung cancer (NSCLC). 5-year results from KN024 are now available. The cost-utility of pembrolizumab can be re-analysed, addressing the uncertainty regarding long-term outcomes highlighted in the previous 2017 pan-Canadian Oncology Drug Review assessment. The objective of this study was to assess the cost-utility of pembrolizumab monotherapy vs chemotherapy as first-line treatment in advanced NSCLC patients, with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% from the Ontario, Canada public payer perspective.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call